Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the FirmGlobeNewsWire • 08/27/26
EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudGlobeNewsWire • 08/27/26
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the FirmBusiness Wire • 08/26/26
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)Business Wire • 08/21/26
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be OverblownSeeking Alpha • 08/19/26
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease GoalZacks Investment Research • 08/18/26
EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU TranscriptSeeking Alpha • 08/18/26
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMDGlobeNewsWire • 08/17/26
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 08/05/26
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)GlobeNewsWire • 07/30/26
Earnings Preview: EyePoint (EYPT) Q2 Earnings Expected to DeclineZacks Investment Research • 07/29/26
This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga • 07/16/26
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26